REBOUND PAIN AFTER PERIPHERAL NERVE BLOCKS

Sponsor
Diskapi Yildirim Beyazit Education and Research Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05635383
Collaborator
(none)
100
2
12
50
4.2

Study Details

Study Description

Brief Summary

In recent years, the use of regional anesthesia techniques as part of multimodal analgesia strategies to maximize pain control in patients has reduced opioid requirements and promoted early mobility and rehabilitation in the perioperative period. Regional anesthesia has benefits, mainly peripheral nerve blocks (PNB), muscle relaxation, and postoperative analgesia, thus allowing for control of postoperative pain and early discharge from the hospital. In addition, using PNB techniques provides:

Hemodynamic stability. Reduced need for a post-anesthetic care unit (PACU). Reduced unplanned hospitalization for pain control. Less airway management. Reduced incidence of opioid-related adverse events. Greater patient satisfaction

The main features of rebound pain are; It is a burning type of severe mechanical-surgical pain unresponsive to intravenous opioid administration, occurring both at rest and in motion, caused by nociceptive inputs within 8-24 hours after PNB. It usually remains severe for 2-6 hours, but the subsequent pain trajectory is consistent with the recovery process expected at surgical intervention. Therefore, rebound pain is temporary and different from persistent post-surgical pain (PPSP). The rebound pain score (RPS), defined by Williams and colleagues, is a standard measure of rebound pain severity and is calculated by subtracting the lowest pain score scored in the first 12 hours before the effect of PNB wears off and the highest pain score during the first 12 hours after PNB resolution. However, a recommended cut-off value for determining the incidence of rebound pain needs to be added. Rebound pain often occurs at night. However, this is probably related to the 8 to 12-hour duration of most single-injection PNBs and the completion of most elective surgeries during daylight hours.

This study aims to reveal the rebound pain profile, determine the risk factors, and contribute to developing strategies that can prevent rebound pain.

Condition or Disease Intervention/Treatment Phase
  • Other: PERIPHERAL NERVE BLOCK

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Investigation of the Frequency and Causes of Rebound Pain Phenomenon After Peripheral Nerve Blocks
Actual Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Jan 1, 2023
Anticipated Study Completion Date :
Aug 1, 2023

Outcome Measures

Primary Outcome Measures

  1. incidence of rebound pain [perioperative period]

    The rebound pain score (RPS) is a standard measure of rebound pain severity and is calculated by subtracting the lowest pain score scored in the first 12 hours before the peripheral nerve block (PNB) wears off and the highest pain score during the first 12 hours after PNB resolution.

Secondary Outcome Measures

  1. rebound pain risk factors [perioperative period]

    such as age, gender, and presence of preoperative pain.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients aged >18 years who underwent elective non-cardiac surgery with the peripheral nerve block
Exclusion Criteria:
  • Patients who did not want to participate in the study, had dementia, severe psychiatric or cognitive dysfunction, ongoing drug/alcohol abuse, known local anesthetic allergy, other injuries requiring opioid analgesics, and pregnant patients

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Medical Science, Yıldırım Beyazıt Training and Research Hospital Ankara Turkey 06000
2 Diskapi Yildirim Beyazit Education and Research Hospital Ankara Turkey

Sponsors and Collaborators

  • Diskapi Yildirim Beyazit Education and Research Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Funda Atar, Principal Investigator, Diskapi Yildirim Beyazit Education and Research Hospital
ClinicalTrials.gov Identifier:
NCT05635383
Other Study ID Numbers:
  • 9.5.2022 137/01
First Posted:
Dec 2, 2022
Last Update Posted:
Dec 2, 2022
Last Verified:
Nov 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Funda Atar, Principal Investigator, Diskapi Yildirim Beyazit Education and Research Hospital

Study Results

No Results Posted as of Dec 2, 2022